United Capital Financial Advisers, LLC Viracta Therapeutics, Inc. Call Options Transaction History
United Capital Financial Advisers, LLC
- $11.5 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VIRX
# of Institutions
21Shares Held
2.3MCall Options Held
1.8KPut Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.63MShares$32,5250.0% of portfolio
-
Black Rock Inc. New York, NY273KShares$5,4650.0% of portfolio
-
Xtx Topco LTD London, X093.4KShares$1,8670.0% of portfolio
-
Hrt Financial LP New York, NY82.7KShares$1,6530.0% of portfolio
-
State Street Corp Boston, MA65.9KShares$1,3170.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $751K
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...